Skip to main content
OpenTrials
Completed

NCT Number: NCT01306591

Bevacizumab for Neovascular Age-related Macular Degeneration

Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Exudative Age-Related Macular Degeneration

Age range

50 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Xiaoxin Li

Beijing, Beijing Municipality, 100044, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of neovascular Age-related macular degeneration
  • Signed informed consent

Exclusion criteria

  • No other ocular fundus diseases

Treatment and study plan

Bevacizumab 1

Drug

Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks

Bevacizumab

Drug

Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week

Primary outcomes

  1. EDTRS visual acuity score

    Time frame: 0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week

    EDTRS visual acuity score is assessed at each timepoint for every group

Secondary outcomes

  1. macular thickness in OCT

    Time frame: 0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week

    macular thickness is assessed at each timepoint for every group

Sponsors and collaborators

Lead sponsor

Peking University People's Hospital

Other

Registry information

Official study title

Randomized Multi-center Clinical Study：Bevacizumab for Neovascular Age-related Macular Degeneration

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Mar 2, 2011
Registry last updated
Mar 2, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.